Nukkleus Financials
This page shows Nukkleus (NUKKW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
T3 Defense’s latest year shows a balance-sheet expansion financed externally while core operations still consume cash and fail to fund themselves.
FY2025’s reported profit was not a cash profit: net income of$78.5M sat beside operating losses and cash burn, with operating income at-$32.6M . At the same time, financing inflow of$182.0M was almost fully absorbed by investing outflow of-$179.8M , so the balance sheet grew without leaving much day-to-day liquidity behind.
The working-capital posture is tight: cash was only
Between FY2022 and FY2024, gross margin improved from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Nukkleus's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nukkleus carries a low D/E ratio of -11.23, meaning only $-11.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 88/100, indicating a strong balance sheet with room for future borrowing.
Nukkleus's current ratio of 0.31 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Nukkleus passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Nukkleus generates $-0.08 in operating cash flow (-$6.2M OCF vs $78.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Nukkleus earns $-211.7 in operating income for every $1 of interest expense (-$32.6M vs $154K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Nukkleus's EBITDA was -$32.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Nukkleus reported $78.5M in net income in fiscal year 2025. This represents an increase of 1022.0% from the prior year.
Nukkleus earned $7.96 per diluted share (EPS) in fiscal year 2025. This represents an increase of 261.5% from the prior year.
Cash & Balance Sheet
Nukkleus generated -$6.2M in free cash flow in fiscal year 2025, representing cash available after capex.
Nukkleus held $2.6M in cash against $0 in long-term debt as of fiscal year 2025.
Nukkleus had 19M shares outstanding in fiscal year 2025. This represents an increase of 13.3% from the prior year.
Margins & Returns
Capital Allocation
Nukkleus invested $31K in capex in fiscal year 2025, funding long-term assets and infrastructure.
NUKKW Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7M | N/A | N/A | N/A | N/A | N/A | $236K+34.7% | $175K |
| Cost of Revenue | $3.3M | N/A | N/A | N/A | N/A | N/A | $18K-63.2% | $50K |
| Gross Profit | $371K | N/A | N/A | N/A | N/A | N/A | $218K+73.6% | $125K |
| R&D Expenses | $274K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $3.5M | N/A | $231K+223.1% | $71K-95.3% | $1.5M-66.7% | $4.5M+8384.4% | $53K+113.3% | $25K |
| Operating Income | -$3.8M | N/A | -$4.8M-355.2% | -$1.0M+30.4% | -$1.5M+66.7% | -$4.5M-280.7% | -$1.2M-15.5% | -$1.0M |
| Interest Expense | $354K | N/A | $36K+84.4% | $20K-88.0% | $165K-62.5% | $439K+44.6% | $304K+664.7% | $40K |
| Income Tax | $38K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$27.1M | N/A | -$16.4M-642.2% | $3.0M | N/A | N/A | $4.5M+375.7% | -$1.6M |
| EPS (Diluted) | $-1.14 | N/A | $-2.02-474.1% | $0.54-97.0% | $18.15+134.9% | $-51.96 | $2.18+342.2% | $-0.90 |
NUKKW Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $315.5M+55.9% | $202.4M+1423.1% | $13.3M+85.9% | $7.1M-16.9% | $8.6M-5.6% | $9.1M+824.8% | $985K-12.1% | $1.1M |
| Current Assets | $22.8M+68.3% | $13.6M+3.3% | $13.1M+88.5% | $7.0M-17.8% | $8.5M-6.9% | $9.1M+841.7% | $966K+36.7% | $706K |
| Cash & Equivalents | $6.4M+144.8% | $2.6M-65.5% | $7.6M+400.9% | $1.5M-65.9% | $4.5M-35.3% | $6.9M+1849229.8% | $373-93.9% | $6K |
| Inventory | $3.5M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $3.6M+619.2% | $506K | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $100.2M+1202.7% | $7.7M | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $279.3M+25.7% | $222.2M+408.3% | $43.7M-27.8% | $60.5M-8.0% | $65.8M-61.8% | $172.5M+2033.7% | $8.1M-39.5% | $13.4M |
| Current Liabilities | $91.6M+110.4% | $43.5M-0.2% | $43.6M-27.8% | $60.4M-6.6% | $64.7M-62.3% | $171.4M+2325.0% | $7.1M-41.7% | $12.1M |
| Long-Term Debt | $3.1M | N/A | $1.6M0.0% | $1.6M0.0% | $1.6M0.0% | $1.6M-52.7% | $3.3M | N/A |
| Total Equity | $36.2M+282.8% | -$19.8M+34.9% | -$30.4M+43.0% | -$53.4M+6.7% | -$57.2M+65.0% | -$163.3M-2201.4% | -$7.1M+42.0% | -$12.2M |
| Retained Earnings | -$149.7M-22.2% | -$122.5M-9.9% | -$111.5M-17.2% | -$95.1M+3.1% | -$98.1M+51.2% | -$201.1M-399.1% | -$40.3M+17.8% | -$49.0M |
NUKKW Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.9M-393.4% | -$999K+60.1% | -$2.5M-85.3% | -$1.4M-0.7% | -$1.3M-294.7% | -$340K+71.6% | -$1.2M-61.9% | -$741K |
| Capital Expenditures | $154K+1151.0% | $12K+220.3% | $4K-20.7% | $5K-51.5% | $10K | N/A | N/A | N/A |
| Free Cash Flow | -$5.1M-402.6% | -$1.0M+59.7% | -$2.5M-85.0% | -$1.4M-0.4% | -$1.4M | N/A | N/A | N/A |
| Investing Cash Flow | -$3.8M+97.8% | -$176.3M-8698.5% | -$2.0M-184.3% | -$705K+13.0% | -$810K+13.5% | -$936K-74385.7% | $1K+408.1% | $248 |
| Financing Cash Flow | $12.5M-92.8% | $173.6M+1782.3% | $9.2M | N/A | N/A | $9.1M+1188.9% | $703K+11.5% | $631K |
| Dividends Paid | $297K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NUKKW Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 10.2% | N/A | N/A | N/A | N/A | N/A | 92.2%+20.6pp | 71.6% |
| Operating Margin | -104.3% | N/A | N/A | N/A | N/A | N/A | -503.5%+84.0pp | -587.5% |
| Net Margin | -743.1% | N/A | N/A | N/A | N/A | N/A | 1887.0%+2809.5pp | -922.4% |
| Return on Equity | -75.1% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8.6% | N/A | -123.2%-165.4pp | 42.2% | N/A | N/A | 452.3%+596.6pp | -144.3% |
| Current Ratio | 0.25-0.1 | 0.31+0.0 | 0.30+0.2 | 0.12-0.0 | 0.13+0.1 | 0.05-0.1 | 0.14+0.1 | 0.06 |
| Debt-to-Equity | 0.09+11.3 | -11.23-11.2 | -0.05-0.0 | -0.030.0 | -0.03-0.0 | -0.01+0.5 | -0.47+0.6 | -1.09 |
| FCF Margin | -139.1% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$19.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.31), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Nukkleus profitable?
Yes, Nukkleus (NUKKW) reported a net income of $78.5M in fiscal year 2025.
What is Nukkleus's EBITDA?
Nukkleus (NUKKW) had EBITDA of -$32.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nukkleus's free cash flow?
Nukkleus (NUKKW) generated -$6.2M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nukkleus's operating cash flow?
Nukkleus (NUKKW) generated -$6.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nukkleus's total assets?
Nukkleus (NUKKW) had $202.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nukkleus's capital expenditures?
Nukkleus (NUKKW) invested $31K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Nukkleus's current ratio?
Nukkleus (NUKKW) had a current ratio of 0.31 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Nukkleus's debt-to-equity ratio?
Nukkleus (NUKKW) had a debt-to-equity ratio of -11.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nukkleus's return on assets (ROA)?
Nukkleus (NUKKW) had a return on assets of 38.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nukkleus's cash runway?
Based on fiscal year 2025 data, Nukkleus (NUKKW) had $2.6M in cash against an annual operating cash burn of $6.2M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Nukkleus's debt-to-equity ratio negative or unusual?
Nukkleus (NUKKW) has negative shareholder equity of -$19.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Nukkleus's Piotroski F-Score?
Nukkleus (NUKKW) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nukkleus's earnings high quality?
Nukkleus (NUKKW) has an earnings quality ratio of -0.08x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Nukkleus cover its interest payments?
Nukkleus (NUKKW) has an interest coverage ratio of -211.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Nukkleus?
Nukkleus (NUKKW) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.